Olema Pharmaceuticals, Inc. (OLMA) - 10-Q Summary
Business Context and Reporting Period
Company: Olema Pharmaceuticals, Inc.
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Olema is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and beyond. Its lead product candidate is palazestrant (OP-1250), a dual-acting estrogen receptor antagonist and degrader. The company is also developing OP-3136, a KAT6 inhibitor. Olema has no approved products and has not generated any product revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(116,289) | $(74,173) |
| Net Loss Per Share (Basic & Diluted) | $(1.12) | $(0.87) |
| Operating Expenses | $125,165 | $82,737 |
| Research & Development (R&D) | $107,017 | $74,526 |
| General & Administrative (G&A) | $18,148 | $8,211 |
| Cash, Cash Equivalents & Marketable Securities | $461,070 | $505,437 (Dec 31, 2025) |
| Long-term Borrowing | $3,000 | $3,000 |
| Accumulated Deficit | $(713,846) | $(597,557) |
Note: The filing does not provide explicit gross margin or operating margin percentages as there is no revenue. Cash flow from operating activities was $(91,883) for the six months ended June 30, 2026.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $42.1 million (57%) year-over-year, driven primarily by higher operating expenses.
- R&D Expense Growth: R&D expenses increased by $32.5 million (44%) due to continued execution of clinical development strategies for palazestrant (OPERA-01 and OPERA-02 trials) and OP-3136, increased manufacturing costs, and higher personnel costs. This increase was partially offset by the absence of a $10.0 million milestone payment to Aurigene recognized in the prior year.
- G&A Expense Growth: G&A expenses increased by $9.9 million (121%), primarily due to a $5.5 million increase in stock-based compensation, a $2.8 million increase in professional fees, and higher payroll costs.
- Capital Raises: The company raised $41.9 million in net proceeds from an at-the-market (ATM) offering during the six months ended June 30, 2026. In the prior year, the company completed a $204.8 million follow-on public offering (Nov 2025) and a $237.0 million private placement (Nov 2024).
- Share Count: Outstanding common shares increased from 81.4 million (Dec 31, 2025) to 87.5 million (June 30, 2026) due to ATM sales, option exercises, and pre-funded warrant exchanges.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash, cash equivalents, marketable securities ($461.1 million as of June 30, 2026), and available credit facility funds are sufficient to fund operations for at least the next 12 months. The company expects to fund operations through mid-2028 based on current plans.
- Clinical Milestones:
- Palazestrant: OPERA-01 (Phase 3 monotherapy) enrollment is complete; top-line results expected in Q1 2027. OPERA-02 (Phase 3 combination with ribociclib) is currently enrolling.
- OP-3136: Phase 1 study is enrolling. Initial monotherapy data presented at ASCO 2026 showed tolerability and anti-tumor activity. A combination study with Bayer's NUBEQA is expected to initiate in Q4 2026.
- Collaborations:
- Novartis: Supply agreement for ribociclib for the OPERA-02 trial. Includes a right of first negotiation for Olema Compound Transactions and potential repayment obligations upon change of control.
- Pfizer: Collaboration for Phase 1b/2 study of palazestrant with atirmociclib.
- Bayer: New agreement for Phase 1b/2 study of OP-3136 with NUBEQA.
- Risks:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding to complete development and commercialization.
- Regulatory & Clinical Risk: No products are approved; clinical trials may fail to demonstrate efficacy or safety. Regulatory approval is not guaranteed.
- Macroeconomic Factors: Geopolitical instability, tariffs (including potential 100% tariffs on certain pharmaceuticals effective Sept 2026), and inflation could increase costs and disrupt supply chains.
- Going Concern: While management believes funds are sufficient for 12+ months, the company has an accumulated deficit of $713.8 million and has never been profitable.
Investor Verification Checklist
- Cash Runway: Verify the specific burn rate and confirm the "mid-2028" funding estimate against current cash balances and projected clinical trial costs.
- OPERA-02 Enrollment: Monitor patient enrollment rates for the pivotal Phase 3 trial with Novartis, as delays could impact the 2027/2028 timeline.
- Tariff Impact: Assess the potential financial impact of the announced 100% tariffs on imported pharmaceutical ingredients effective September 29, 2026.
- Stock-Based Compensation: Review the trajectory of stock-based compensation expenses, which increased significantly ($23.1M in H1 2026 vs $9.1M in H1 2025), as this impacts cash flow and dilution.
- Pre-funded Warrants: Note the 13.6 million pre-funded warrants outstanding (exercisable at $0.0001) which are included in diluted share counts and could impact future liquidity if exercised.